基于优化分治表的远程数据审计方法研究

为了降低远程数据审计中的计算和通信成本,提出一种高效的远程大数据审计方法。数据所有者通过Key Gen算法生成公共密钥和秘密密钥;为了对外包数据块的完整性进行验证,数据所有者生成随机数据块和质询消息。当云服务器接收到质询消息时,数据所有者基于数据块标签的代数签名,远程地检查文件的正确性。同时设计分治表DCT(Divide and Conquer Table)数据结构,并优化以支持动态数据更新等操作。实验结果表明:所提DCT数据结构通过降低数据块移动数量,有效地降低了动态数据更新操作的处理时间。与其他方法相比,所提方法显著降低了云计算中对大型外包文件进行动态数据更新的计算成本,且具备安全性。

基于有限域代数签名分治表的大数据云存储远程审计

为提高大数据存储过程的审计效率,提出基于有限域代数签名分治表远程数据检查RDC的云计算大数据存储审计方法。首先,通过使用外包文件的代数签名,利用底层字段算术运算完成云存储中数据完整性的远程检测,所提数据审计方法对客户端和云服务端具有相对较低的计算和通信成本。其次,设计了分治表D&CT作为一种新的数据结构,以有效地支持动态数据操作,如插入、追加、删除和修改操作。采用D&CT方法可令所提RDC方案适用于各种大小的文件云存储过程分析。最后,通过仿真实验,验证了所提方法在大数据云存储过程中的有效性。

基于分治表的云存储数据完整性审计方案

本文基于分治表和双线性对技术,提出基于分治表的云存储数据完整性审计方案。提出的方案不但能满足云存储数据的完整性审计的安全要求,同时设计的数据结构分治表(DCT)能更加高效的支持外包的动态操作。云存储数据完整性检查受到了学术各界的广泛关注,而且现有的数据审计方案并不能很好数据动态更新问题。

一种高效的基于分治邻接表的动态完整性审计方案

随着云存储服务的广泛应用,数据的完整性审计成为研究热点,取得了丰硕的研究成果.但是,现有的大部分数据完整性审计方案并不能很好地处理数据动态更新的问题.为了实现高效的动态完整性审计,本文设计一种新的分治邻接表(divide and conquer adjacency table,D\&CAT)数据结构,在基于代数签名的基本审计方案中引入异或同态函数保护审计过程中的数据隐私.分治邻接表结构在外包数据更新操作时,当删除或者插入数据块(i)时,只需要修改对应数据块的链表指针,就可以有效提高外包数据更新操作的效率.实验结果表明,本方案与其它方法相比,可以显著降低数据审计中数据更新的计算开销.

Research Progress in the Use of Drugs for Breast Cancer Targeted Therapy

In recent years,many significant advances have been made on molecular target therapy to aim directly at epidermal growth factor receptors and vascular endothelial growth factor in breast cancers.Clinical studies of such agents as trastuzumab,lapatinib,erlotinib and bevacituzumab have been widely conducted.This paper will review the recent research progress related to targeted therapy.

Gene expression profile analyses of mice livers injured by Leigongteng

AIM： To analyze the gene expression profiles of mice livers injured by Leigongteng and explore the relationship between the differentially expressed genes and liver damage. METHODS： The experimental mice were randomly divided into a control group and a liver-injured group in which the mice were administrated 33 μγ, of triptolide/ kg per day for 30 d. Liver mRNAs were extracted from animals in both groups and were reverse-transcribed to cDNA with dUTP labeled by different fluorescence （Cy3, Cy5） as hybridization probes. The mixed probes were hybridized with oligonucleotide microarray chips. The fluorescent signal results were acquired by scanner and analyzed with software. RESULTS： Among the 35852 target genes, 29 genes were found to be significantly differentially expressed, with 20 genes up-regulated and 9 genes down-regulated. The reliability of the differentially expressed genes was validated by RT-PCR experiments of 5 randomly selected differentially expressed genes. CONCLUSION： Based on the biological functions of the differentially expressed genes, it is obvious that the occurrence and development of liver damage induced by Leigongteng in mice are highly associated with immune response, metabolism, apoptosis and the cell skeleton of liver cells. This might be important for elucidating the regulatory network of gene expression associated with liver damage and it may also be important for discovering the pathogenic mechanisms of liver damage induced by Leigongteng.

Liver alveolar echinococcosis in China: Clinical aspect with relative basic research

This paper deals with all aspects of liver alveolar echinococcosis (AE) including epidemiology, pathology, clinical manifestations, imaging examinations, diagnosis and differential diagnosis, surgical treatment and chemotherapy.The review is not only based on personal clinical experiences but also in combination with relative basic research such as proliferation and growth of alveococcus, preclinical studies of a novel compound extracted from TCM for treatment of liver AE, and molecular immunology used for specific AE diagnosis, etc.

Long-term outcome and efficacy of endoscopic hemorrhoid ligation for symptomatic internal hemorrhoids

AIM:To assess the long-term outcome of endoscopic hemorrhoid ligation (EHL) for the treatment of symptomatic internal hemorrhoids.METHODS:A total of 759 consecutive patients (415 males and 344 females) were enrolled.Clinical presentations were rectal bleeding (593 patients) and mucosal prolapse (166 patients).All patients received EHL at outpatient clinics.Hemorrhoid severity was classified by Goligher's grading.The mean follow-up period was 55.4 mo (range,45-92 mo).RESULTS:The number of band ligations averaged 2.35 in the first session for bleeding and 2.69 for prolapsed patients.Bleeding was controlled in 587 (98.0%) patients,while prolapse was reduced in 137 (82.5%) patients.After treatment,93 patients experienced anal pain and 48 patients had mild bleeding.Patient subjective satisfaction was 93.6%.Repeat treatment or surgery was performed if symptoms were not relieved in the first session.In the bleeding group,the recurrence rate was 3.7% (22 patients) at 1 year,and 6.6%and 13.0% at 2 and 5 years.In the prolapsed group,the recurrence rate was 3.0%,9.6% and 16.9% at 1,2 and 5 years,respectively.CONCLUSION:EHL is an easy and well-tolerated procedure for the treatment of symptomatic internal hemorrhoids,with good long-term results.

Molecular Mechanisms Contributing to Resistance to Tyrosine Kinase-Targeted Therapy for Non-Small Cell Lung Cancer

One of the most important pathways in non-small cell lung cancer(NSCLC) is the epidermal growth factor receptor(EGFR) pathway. This pathway affects several crucial processes in tumor development and progression,including tumor cell proliferation,apoptosis regulation,angiogenesis,and metastatic invasion.Targeting EGFR is currently being intensely explored.We are witnessing the development of a number of potential molecular-inhibiting treatments for application in clinical oncology.In the last decade,the tyrosine kinase(TK) domain of the EGFR was identified in NSCLC patients,and it has responded very well with a dramatic clinical improvement to TK inhibitors such are gefitinib and erlotinib.Unfortunately,there were primary and/or secondary resistance to these treatments,as shown by clinical trials.Subsequent molecular biology studies provided some explanations for the drug resistance phenomenon.The molecular mechanisms of resistance need to be clarified.An in-depth understanding of these targeted-therapy resistance may help us explore new strategies for overcoming or reversing the resistance to these inhibitors for the future of NSCLC treatment.

Hydrogen Storage Capacity of C120 Nanocapsules： Density Functional Theory Based Treatments

The adsorption of hydrogen molecule on the external surface of pure 0120 nanocapsule and endohedrallyH2 @C120 complex has been examined using the density functional theory calculations. Several different bonding configu- rations are considered for the hydrogen molecule approaching the outer surface of the considered nanocages. It has been found that the adsorbed H2 molecule bound weakly to the outer surface of the pure C1~0 nanocapsules in agreement with the recent experimental and theoretical results while, it prefers to be adsorbed rather strongly on the side wall of the endohedrally /-/2@C120 complex. The adsorption of a single layer and bi-layer of two tt2 molecules on the most stable states of the considered H2@C120 complex appears to be feasible, although the molecules of the second layer are weakly bound. Furthermore, it is found that the formation of 100% coverage is favorable thermodynamically, which corresponds to about 20% by weight storage of 1-12 molecules. Thus, surprisingly, we arrive at the prediction that the C120 nanocapsules can be implemented as a novel material for energy storage.

Update on immunoglobulin a nephropathy.Part Ⅱ:Clinical,diagnostic and therapeutical aspects

Immunoglobulin A nephropathy （IgAN） is characterized by different clinical manifestations and by long-term different outcomes. Major problem for the physicians is to understanding which patients are at risk of a disease evolution and to prescribe the right therapy to the right patients. Indeed, in addition to patients with a stable disease with no trend to evolution or even with a spontaneous recovery, patients with an active disease and patients with a rapidly evolving glomeru-lonephritis are described. Several histopathological, biological and clinical markers have been described and are currently used to a better understanding of patients at risk, to suggest the right therapy and to monitor the therapy effect and the IgAN evolution over time. The clinical markers are the most reliable and allow to divide the IgAN patients into three categories： The low risk patients, the intermediate risk patients and the high risk patients. Accordingly, the therapeutic measures range from no therapy with the only need of repeated controls, to supportive therapy eventually associated with low dose immunosuppression, to immunosuppressive treat-ment in the attempt to avoid the evolution to end stage renal disease. However the current evidence about the different therapies is still matter of discussion. New drugs are in the pipeline and are described. They are object of randomized controlled trials, but studies with a number of patients adequately powered and with a long follow up are needed to evaluate effcacy and safety of these new drugs.